The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1034
August 28, 1998
View Complete Issue         Table of Contents 2019 
Risedronate for Paget's Disease of Bone
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Risedronate for Paget's Disease of Bone
August 28, 1998 (Issue: 1034)
Risedronate (Actonel - Procter & Gamble), a pyridinyl bisphosphonate, has been approved by the FDA for oral treatment of Paget's disease of bone. Characterized by excessive bone resorption, bony deformity, disorganized bone remodeling and...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Risedronate for Paget's Disease of Bone
Article code: 1034b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.